Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REN001 in McArdle Disease
NCT04226274Phase 1Completed
- Sponsor
- Reneo Pharmaceuticals
- Start
- Dec 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of mavodelpar in Glycogen storage disease type 5 (GSD5), sponsored by Reneo Pharmaceuticals. Primary endpoint: Adverse Events at 12 weeks. Started Dec 2019; status: completed.
02
Drugs
mavodelpar
03
Conditions
Glycogen storage disease type 5 (GSD5)
Beyond the preview
Go deeper on NCT04226274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04226274.